Finasteride for Androgenetic Alopecia

Verdict: Works for male pattern baldness

For men with androgenetic alopecia, daily oral finasteride is consistently shown to slow shedding and modestly regrow hair, but the benefit reverses within about a year of stopping and carries sexual side-effect warnings. The evidence does not extend to women, where results are negative or too limited to support use.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

Multiple large double-blind RCTs in men point the same direction: the Propecia phase III pivotal trial (PMID 9777765, n=1879), a frontal hair-loss trial (PMID 10365924, n=326), and a trial in men aged 41-60 (PMID 12695131, n=425) all reported significant hair gains at 1 mg/day, and a systematic review/meta-analysis (PMID 20956649, n=3927) pooled a consistent effect. This concordance is why the verdict is positive rather than neutral.

The grade stays at Preliminary rather than top-tier because the pivotal trials were industry-funded (a flagged conflict of interest) and regulators temper the picture. The US FDA approves finasteride but warns of sexual dysfunction that can persist after discontinuation; the UK NHS notes it does not work for everyone and is not NHS-funded for hair loss; and WHO pharmacovigilance data carry sexual-dysfunction safety signals.

Clinical bodies (Mayo Clinic, Harvard Health, the American Academy of Dermatology) back it as a first-line option for men, with Harvard citing 80-90% who maintain or regrow hair, while stressing that gains are lost within roughly a year of stopping. Crucially, this conclusion applies only to men: a trial in postmenopausal women found no benefit (PMID 11050579), and the female evidence is otherwise small and uncontrolled (PMID 16549704).

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.66
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
80%
Highly consistent evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.85
L5 Clinical bodiesAuthoritative stance
0.85
L11 AI re-checkIndependent read
0.95
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.663
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Finasteride in the treatment of men with androgenetic alopecia (Propecia phase III pivotal)
PMID: 9777765 1998 RCT (double-blind) n = 1,879
Finding: Significant increase in hair count vs placebo at week 48 and 96 (mean +86 hairs/inch² at 1y vs placebo loss); 83% of finasteride men had no further loss vs 28% placebo (p<0.001).
🟢 High quality ⚠️ Industry-funded Effect size: MD +86 hairs/inch² at 12 months vs placebo (p<0.001)
View on PubMed
Finasteride in the treatment of men with frontal male pattern hair loss (Leyden 1999)
PMID: 10365924 1999 RCT (double-blind) n = 326
Finding: Finasteride significantly improved frontal hair count vs placebo (mean +49.5 vs -9.6 hairs, p<0.001); investigator photographic assessment improved in 51% vs 7% placebo.
🟢 High quality ⚠️ Industry-funded Effect size: MD ~59 hairs/inch² frontal scalp at 48 wks (p<0.001)
View on PubMed
Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss (Whiting 2003)
PMID: 12695131 2003 RCT (double-blind) n = 425
Finding: Finasteride sustained benefit over 2 years in older men: significantly higher hair counts and global assessment scores vs placebo (p<0.001); efficacy comparable to younger cohort.
🟢 High quality ⚠️ Industry-funded Effect size: Net MD ~277 hairs/inch² at 2y vs placebo (p<0.001)
View on PubMed
Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review (Mella 2010)
PMID: 20956649 2010 統合分析 n = 3,927
Finding: Pooled MD +9.42 hairs/cm² at 12 months in men (95% CI 7.20-11.65, p<0.001); investigator and patient ratings significantly improved; adverse-event risk small but elevated for sexual dysfunction (RR ~1.4).
🟢 High quality Academic Effect size: MD +9.42 hairs/cm² at 1 year (95% CI 7.20-11.65)
View on PubMed
Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia (Price 2000)
PMID: 11050579 2000 RCT (double-blind) n = 137
Finding: No significant difference between finasteride 1 mg and placebo on any endpoint in postmenopausal women with FPHL — null result.
🟢 High quality ⚠️ Industry-funded Effect size: Null (no significant MD)
View on PubMed
Finasteride treatment of female pattern hair loss (Iorizzo 2006)
PMID: 16549704 2006 RCT (open-label) n = 37
Finding: 62% of premenopausal women with FPHL showed clinical improvement on 2.5 mg finasteride + OC over 12 months; small open-label, no placebo arm.
🟠 Limited quality Academic Effect size: 62% responder rate (no controlled comparator)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
Sexual dysfunction that continued after discontinuation source↗
L4c UK NHS
Cautious
Finasteride and minoxidil are the main treatments for male pattern baldness. ... Finasteride and minoxidil are not available on the NHS. ... Both can have side effects, and they do not work for everyone. ... For benign prostate enlargement, finasteride and dutasteride are 5-alpha reductase inhibitors which block the hormones that cause the prostate to grow. source↗
L4d TW TFDA / 衛福部
Cautious
Finasteride(柔沛 Propecia 1mg、波斯卡 Proscar 5mg)為醫師處方用藥,仿單載明可能引起性功能障礙(性慾減退、勃起功能障礙、射精異常),部分症狀於停藥後仍可能持續。 source↗
L4e WHO
Cautious
Finasteride has an established WHO International Nonproprietary Name (INN). It is NOT listed on the WHO Model List of Essential Medicines (24th edition, 2025); BPH/androgenetic alopecia treatments are generally outside EML scope. VigiBase (WHO global pharmacovigilance database, managed by UMC Uppsala) has accumulated disproportionality signals for sexual dysfunction associated with finasteride … source↗
L5b Mayo Clinic
Supportive
If you are taking this medicine for male pattern hair loss, it may take at least 3 months to see an effect. The medicine will not cure hair loss, but it will cause scalp hair to grow. The hair growth will only last as long as the medicine is used. The new hair will be lost within 1 year after the medicine is stopped. source↗
L5d Harvard Health
Supportive
Finasteride (Propecia) is an FDA-approved oral medication for male pattern hair loss that works by blocking the conversion of testosterone to dihydrotestosterone (DHT), the hormone that shrinks hair follicles in genetically susceptible men. In clinical trials, about 80% to 90% of men taking 1 mg daily either maintained or regrew hair, though benefit is lost within a year of stopping. Sexual sid… source↗
L5e Specialty Society (condition-mapped)
Supportive
The U.S. Food and Drug Administration (FDA) approved this medication to treat male pattern hair loss. When taken as directed, finasteride can: Slow down hair loss [and] Stimulate new hair growth. Finasteride is a pill that you take once a day. ... If finasteride works for you, you will need to keep taking it to continue getting results. Once you stop, you'll start losing hair again. source↗

📰Related guidesEditorial coverage citing this evidence · 4 articles

PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-androgenetic-alopecia-INT-finasteride-001 繁體中文版 →